Cost-Effectiveness analysis of the 21-Gene platform for guiding treatment decisions for early Hormone-Positive breast cancer: the perspective of the Brazilian public health system
The use of the 21-gene platform can be cost effective for guiding treatment decisions in early ER- positive breast cancer treated by the SUS for patients classified at high risk on the basis of clinical factors if a cost limit of US$ 1,505.46 per test is considered.
Authors
- Luiz Vinícius de Alcantara Sousa (ORCID: https://orcid.org/0000-0002-6895-4914)
- Daniel de Iracema Gomes Cubero (ORCID: https://orcid.org/0000-0002-1936-2605)
- Jean Henri Maselli-Schoueri (ORCID: https://orcid.org/0000-0003-2509-3592)
- Fernando Luiz Affonso Fonseca (ORCID: https://orcid.org/0000-0003-1223-1589)
- Auro del Giglio (ORCID: https://orcid.org/0000-0002-2009-824X)
Institutions
- Faculdade de Medicina do ABC (BR)
- Centro de Pesquisas Oncológicas (BR)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1186/s12913-025-13230-6
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo